Haber M - Search Results

1

Determining the repertoire of IGH gene rearrangements to develop molecular markers for minimal residual disease in B-lineage acute lymphoblastic leukemia.

Brisco MJ, Latham S, Sutton R, Hughes E, Wilczek V, van Zanten K, Budgen B, Bahar AY, Malec M, Sykes PJ, Kuss BJ, Waters K, Venn NC, Giles JE, Haber M, Norris MD, Marshall GM, Morley AA. Brisco MJ, et al. Among authors: haber m. J Mol Diagn. 2009 May;11(3):194-200. doi: 10.2353/jmoldx.2009.080047. Epub 2009 Mar 26. J Mol Diagn. 2009. PMID: 19324994 Free PMC article.

2

Reduced drug accumulation as the mechanism of extreme clinical resistance to methotrexate in the human T-cell leukemia xenograft, LALW-2.

Norris MD, Haber M, Kavallaris M, Brian MJ, Lutze LH, White L, Stewart BW. Norris MD, et al. Among authors: haber m. Cancer. 1991 Sep 1;68(5):981-7. doi: 10.1002/1097-0142(19910901)68:5<981::aid-cncr2820680512>3.0.co;2-w. Cancer. 1991. PMID: 1913492

3

Atypical multidrug resistance in a therapy-induced drug-resistant human leukemia cell line (LALW-2): resistance to Vinca alkaloids independent of P-glycoprotein.

Haber M, Norris MD, Kavallaris M, Bell DR, Davey RA, White L, Stewart BW. Haber M, et al. Cancer Res. 1989 Oct 1;49(19):5281-7. Cancer Res. 1989. PMID: 2569932

4

Atypical multidrug resistance in CCRF-CEM cells selected for high level methotrexate resistance: reactivity to monoclonal antibody C219 in the absence of P-glycoprotein expression.

Norris MD, Haber M, King M, Davey RA. Norris MD, et al. Among authors: haber m. Biochem Biophys Res Commun. 1989 Dec 29;165(3):1435-41. doi: 10.1016/0006-291x(89)92764-2. Biochem Biophys Res Commun. 1989. PMID: 2575383

5

Therapy-induced drug resistance in a human leukemia line (LALW-2). A clinically relevant model.

White L, Haber M, Brian MJ, Norris MD, Trickett A, Sosula L, Tiley C, Stewart BW. White L, et al. Among authors: haber m. Cancer. 1989 Jun 1;63(11):2103-10. doi: 10.1002/1097-0142(19890601)63:11<2103::aid-cncr2820631106>3.0.co;2-n. Cancer. 1989. PMID: 2720561

6

Resistance to drugs associated with the multidrug resistance phenotype following selection with high-concentration methotrexate.

Haber M, Reed C, Kavallaris M, Norris MD, Stewart BW. Haber M, et al. J Natl Cancer Inst. 1989 Aug 16;81(16):1250-4. doi: 10.1093/jnci/81.16.1250. J Natl Cancer Inst. 1989. PMID: 2754745

7

Characterization of clonal immunoglobulin heavy chain and I cell receptor gamma gene rearrangements during progression of childhood acute lymphoblastic leukemia.

Marshall GM, Kwan E, Haber M, Brisco MJ, Sykes PJ, Morley AA, Toogood I, Waters K, Tauro G, Ekert H, et al. Marshall GM, et al. Among authors: haber m. Leukemia. 1995 Nov;9(11):1847-50. Leukemia. 1995. PMID: 7475273

8

Detection of evolving immunoglobulin heavy-chain gene rearrangements in acute lymphoblastic leukemia: a PCR-based assay employing overlapping DJH primers.

Norris MD, Kwan E, Haber M, Marshall GM. Norris MD, et al. Among authors: haber m. Leukemia. 1995 Oct;9(10):1779-82. Leukemia. 1995. PMID: 7564525

9

An assay for the determination of reduced methotrexate accumulation in cells displaying limited viability in vitro.

Haber M, Norris MD, Kavallaris M, Camacho M, Madafiglio J, Baker CJ, White L, Stewart BW. Haber M, et al. Cancer Lett. 1995 Oct 20;97(1):49-55. doi: 10.1016/0304-3835(95)03950-2. Cancer Lett. 1995. PMID: 7585477

10

Increased retinoic acid receptor gamma expression suppresses the malignant phenotype and alters the differentiation potential of human neuroblastoma cells.

Marshall GM, Cheung B, Stacey KP, Camacho ML, Simpson AM, Kwan E, Smith S, Haber M, Norris MD. Marshall GM, et al. Among authors: haber m. Oncogene. 1995 Aug 3;11(3):485-91. Oncogene. 1995. PMID: 7630632

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

694 results

Search Page